NASDAQ / LIVE COMPANY INTELLIGENCE

Coya Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCOYA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / COYA COVERAGE

What’s moving Coya Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Why Coya Therapeutics, Inc.’s (COYA) Stock Is Up 5.01%

Why Coya Therapeutics, Inc.’s (COYA) Stock Is Up 5.01%

Investors are testing whether Coya Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?

Investors are testing whether Coya Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination ...

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination ...

The story matters when it changes Coya Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering

Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering

The story matters when it changes Coya Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest COYA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-12 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-16 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-25 · Period 2026-06-25SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗8-KMaterial company eventFiled 2026-05-12 · Period 2026-05-12SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-05-13 · Period 2026-06-25SEC ↗SCHEDULE 13G/AOfficial SEC filingFiled 2026-07-27SEC ↗
EARNINGS / QUARTERLY TRACKER

Coya Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.